Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.small Co.2 Regulatory News (BSC)

Share Price Information for Br.small Co.2 (BSC)

Share Price is delayed by 15 minutes
Get Live Data
50.55    0.00 (0.00%)
Bid:
49.60
Ask:
51.50
Spread: 1.90 (3.831%)
Market Cap: £193.32m
BSC Live PriceLast checked at - London Stock Exchange

Intraday Br.small Co.2 Share Chart

Interim Management Statement

19 Nov 2008 10:48

RNS Number : 4691I
British SmallerTechCompaniesVCT2PLC
19 November 2008
 

BRITISH SMALLER TECHNOLOGY COMPANIES VCT 2 PLC ("the Company")

INTERIM MANAGEMENT STATEMENT

For the quarter ended 30 September 2008

British Smaller Technology Companies VCT 2 plc presents its interim management statement for the quarter ended 30 September 2008. This constitutes the Company's second interim management statement for the financial year ending 31 December 2008, as required by the UK Listing Authority's Disclosure and Transparency Rule 4.3.

The unaudited net asset value per Ordinary share as at 30 September 2008 was 79.7 pence. This is a decrease of 3.9% over the net asset value of 82.9 pence per share at 30 June 2008.  The reduction is largely attributed to the recognition of the special and interim dividend paid to shareholders in September and totalling 4 pence per share. Hence the total return, calculated by reference to the net asset value plus cumulative dividends paid has increased from 94.9p per share at 30 June 2008 to 95.7 pence per share at 30 September 2008, an increase of 0.8%.  

In addition to the dividend, the last three months have seen the value of the AiM portfolio depressed given the market conditions and a £94k reduction in the portfolio has been recognised.  This represents a 6% reduction in the value of the AiM portfolio during the quarter. A review of the unquoted portfolio has identified some ups and downs, but minimal net impact on the value of the unquoted portfolio overall. The reduction in the value of the AiM portfolio has been offset by the recovery in the market value of the gilts, which have increased £110k during the period. At 30 September 2008, the Company held cash and Gilts representing 42.5% of the net asset value. 

This quarter has seen the inclusion of £164,000 in respect of the reclaim for irrecoverable VAT in line with the ruling by HMRC.

There has been no movement in the number of Ordinary shares, 16,641,257 Ordinary shares being in issue at both 31 December 2007 and 30 June 2008.

The Company has completed one investment in the quarter, being a £52,000 follow on equity investment in Manchester based computer chip designer Silistix Limited Disposals of £3,500 related to the scheduled loan repayments made by RMS Group Limited.

Net assets at 30 September 2008 comprised the following:

£000

% of net assets

Unquoted investments at fair value

5,815

43.8

Quoted investments at bid price

1,519

11.5

Total venture capital investments

7,334

55.3

Cash and cash equivalents

5,633

42.5

Other net current assets

295

2.2

Net assets

13,262

100.0

The net asset value per Ordinary share at 30 September 2008 was 79.7 pence. The net asset value remains significantly in excess of the current share price.

The ten largest investments by valuation at 30 September 2008 were as follows:

£000

% of net assets

Digital Healthcare

1,650

12.5

Immunobiology

850

6.4

Silistix

719

5.4

Primal Pictures

642

4.8

Pressure Technologies

520

3.9

ART

484

3.7

RMS

435

3.3

Cater Plus

345

2.6

DxS

320

2.4

Harvey Jones

278

2.1

Top ten investments

6,243

47.1

Other investments

1,091

8.2

Total venture capital investments

7,334

55.3

Quoted investments are carried at bid price at 30 September 2008. Unquoted investment are carried at fair value as at 30 September 2008 as determined by the directors.

During the three months ended 30 September 2008 the following significant investment transactions took place (all companies are unquoted except where otherwise indicated):

Follow-on Investments:

Name of company:

Business activity:

Amount invested £000

Silistix Ltd

Silicon chip design

52

52

In this period the Company has seen its underlying net asset value increase by 0.8 pence per share after the payment of an interim dividend of 2 pence per share and a special dividend of 2 pence share. It is pleasing to note that the residual net asset value has both increased and currently comprises 42.5% in gilts and cash.

With the principal investments in the portfolio all having secured funding with little exposure to financial leverage the portfolio is itself well placed to take advantage of expansion opportunities as they arise.

There has been a marked increase in the number of investment opportunities being presented. The Company's liquidity is good but your board will be seeking to increase this through a non-prospectus top up offer early in the New Year.

 

19 November 2008

For further information please contact:

David Hall YFM Private Equity Tel: 0161 832 7603

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSGUGMCGUPRGUB
Date   Source Headline
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding
4th Apr 20233:24 pmRNSDirector/PDMR Shareholding
4th Apr 20233:22 pmRNSIssue of Equity and Close of Offers
29th Mar 20238:40 amRNSTransaction in Own Shares
27th Mar 20236:00 pmRNSClose of Offers to new Applications
27th Mar 20236:00 pmRNSClose of Offers to new Applications
23rd Mar 202311:30 amRNSPublication of Circular
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
20th Mar 20233:00 pmRNSAnnual Financial Report
14th Feb 20234:35 pmRNSOffer Update
14th Feb 20234:35 pmRNSOffer Update
11th Jan 202310:00 amRNSPayment of Dividend and Issue of Equity
19th Dec 20228:50 amRNSTransaction in Own Shares
6th Dec 20229:58 amRNSOffer Update
6th Dec 20229:58 amRNSOffer Update
30th Nov 202212:30 pmRNSPublication of a Prospectus
30th Nov 202212:30 pmRNSPublication of a Prospectus
25th Nov 20229:30 amRNS3rd Quarter Results
4th Nov 20228:30 amRNSDividend Declaration
24th Oct 20229:00 amRNSChange of Registrar
3rd Oct 20221:30 pmRNSOffer Update
3rd Oct 20221:30 pmRNSOffer Update
3rd Oct 202212:24 pmRNSPayment of Dividend and Issue of Equity
28th Sep 202211:12 amRNSTransaction in Own Shares
20th Sep 20229:30 amRNSHalf-year Report
4th Aug 202211:45 amRNSDividend Declaration
2nd Aug 20221:15 pmRNSStatement re intention to fundraise
2nd Aug 20221:15 pmRNSStatement re intention to fundraise
29th Jun 202210:00 amRNSPurchase of Own Securities and Net Asset Value
21st Jun 20223:00 pmRNSInterim Management Statement
13th Jun 20223:51 pmRNSResult of AGM
6th May 20229:14 amRNSPayment of dividend and Issue of Equity
30th Mar 20228:00 amRNSTransaction in Own Shares
21st Mar 20221:15 pmRNSAnnual Financial Report
25th Feb 202212:03 pmRNSResult of General Meeting
31st Jan 202212:00 pmRNSPublication of Circular
7th Jan 202211:15 amRNSDirector/PDMR Shareholding
7th Jan 202211:15 amRNSDirector/PDMR Shareholding
7th Jan 202211:15 amRNSDirector/PDMR Shareholding
7th Jan 202211:15 amRNSIssue of Equity and Close of Offers
16th Dec 20219:57 amRNSTransaction in Own Shares
6th Dec 202110:37 amRNSPublication of Supplementary Prospectus
6th Dec 202110:33 amRNSPublication of Supplementary Prospectus
18th Nov 20218:08 amRNSInterim Management Statement
16th Nov 202110:06 amRNSPayment of dividend and allotment of shares
12th Nov 20217:00 amRNSClose of Offers to New Applications
12th Nov 20217:00 amRNSClose of Offers to New Applications
25th Oct 202112:08 pmRNSPayment of Dividend and Issue of Equity
19th Oct 202110:14 amRNSNet Asset Value and Dividend Re-investment Scheme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.